Explore the vast range of titles available.

Single-cell analysis is critical to revealing cell-to-cell heterogeneity that would otherwise be lost in ensemble analysis. Detailed lipidome characterization for single cells is still far from mature, especially when considering the highly complex structural diversity of lipids and the limited sample amounts available from a single cell. We report the development of a general strategy enabling single-cell lipidomic analysis with high structural specificity. Cell fixation is applied to retain lipids in the cell during batch treatments prior to single-cell analysis. In addition to tandem mass spectrometry analysis revealing the class and fatty acyl-chain for lipids, batch photochemical derivatization and single-cell droplet treatment are performed to identify the C=C locations and sn -positions of lipids, respectively. Electro-migration combined with droplet-assisted electrospray ionization enables single-cell mass spectrometry analysis with easy operation but high efficiency in sample usage. Four subtypes of human breast cancer cells are correctly classified through quantitative analysis of lipid C=C location or sn -position isomers in ~160 cells. Most importantly, the single-cell deep lipidomics strategy successfully discriminates gefitinib-resistant cells from a population of wild-type human lung cancer cells (HCC827), highlighting its unique capability to promote precision medicine. Analyzing the lipidomes of single cells remains a challenge. Here, the authors present a strategy to identify class, fatty acyl-chain, C=C locations and sn -positions of lipids in single cells, and use their method to identify individual gefitinib-resistant cells in a wild-type lung cancer cell population.

Lipids play a pivotal role in biological processes and lipid analysis by mass spectrometry (MS) has significantly advanced lipidomic studies. While the structure specificity of lipid analysis proves to be critical for studying the biological functions of lipids, current mainstream methods for large-scale lipid analysis can only identify the lipid classes and fatty acyl chains, leaving the C=C location and sn -position unidentified. In this study, combining photochemistry and tandem MS we develop a simple but effective workflow to enable large-scale and near-complete lipid structure characterization with a powerful capability of identifying C=C location(s) and sn -position(s) simultaneously. Quantitation of lipid structure isomers at multiple levels of specificity is achieved and different subtypes of human breast cancer cells are successfully discriminated. Remarkably, human lung cancer tissues can only be distinguished from adjacent normal tissues using quantitative results of both lipid C=C location and sn -position isomers. Coupling photochemical derivatization with tandem mass spectrometry enables C=C-isomer resolved lipidomics. Here, the authors further develop this approach into a shotgun lipidomics workflow that allows simultaneous characterization of lipid C=C locations and sn -positions in complex biological samples.

Chronic inflammation is a prerequisite for the development of cancers. Here, we present the framework of a novel theory termed as Cancer Evolution-Development ( Cancer Evo-Dev ) based on the current understanding of inflammation-related carcinogenesis, especially hepatocarcinogenesis induced by chronic infection with hepatitis B virus. The interaction between genetic predispositions and environmental exposures, such as viral infection, maintains chronic non-resolving inflammation. Pollution, metabolic syndrome, physical inactivity, ageing, and adverse psychosocial exposure also increase the risk of cancer via inducing chronic low-grade smoldering inflammation. Under the microenvironment of non-resolving inflammation, pro-inflammatory factors facilitate the generation of somatic mutations and viral mutations by inducing the imbalance between the mutagenic forces such as cytidine deaminases and mutation-correcting forces including uracil–DNA glycosylase. Most cells with somatic mutations and mutated viruses are eliminated in survival competition. Only a small percentage of mutated cells survive, adapt to the hostile environment, retro-differentiate, and function as cancer-initiating cells via altering signaling pathways. These cancer-initiating cells acquire stem-ness, reprogram metabolic patterns, and affect the microenvironment. The carcinogenic process follows the law of “mutation-selection-adaptation”. Chronic physical activity reduces the levels of inflammation via upregulating the activity and numbers of NK cells and lymphocytes and lengthening leukocyte telomere; downregulating proinflammatory cytokines including interleukin-6 and senescent lymphocytes especially in aged population. Anti-inflammation medication reduces the occurrence and recurrence of cancers. Targeting cancer stemness signaling pathways might lead to cancer eradication. Cancer Evo-Dev not only helps understand the mechanisms by which inflammation promotes the development of cancers, but also lays the foundation for effective prophylaxis and targeted therapy of various cancers.

Background Kidney cancer (KC) is a major global health concern. Considering the significant impact of premature morbidity and mortality in young adults on the global disease burden, it is essential to conduct a longitudinal study on KC in young adults to develop cost-effective interventions. Methods Age-standardized rates (ASRs) including incidence rate (ASIR), mortality rate (ASMR), and disability-adjusted life-years (DALYs) rate (ASDR), and ASDR attributable to risk factors (obesity, smoking, exposure to trichloroethylene, etc.) of KC were analyzed using Global Burden of Disease Study 2021 data (1990–2021), in the whole population and among young adults aged 20–39 years by sex, age, and socio-demographic index (SDI). Mortality to incidence ratio (MIR), percentage change, estimated annual percentage change (EAPC) and the correlation between ASR and SDI were evaluated. Future forecasts of KC burden until 2050 were performed. Results ASIR among young adults aged 20–39 years increased (EAPC = 1.13%, P  < 0.001), ranking second only to those over 80 years old. ASMR declined, with the slowest decrease observed among those aged 20–39 years (EAPC = -0.12%; P  = 0.003), mainly due to the upward trend observed among males (EAPC = 0.11%, P  = 0.022). No change of ASDR was detected among young adults despite of decreasing trend in the whole population. ASDR attributable to high BMI exhibited an overall increasing trend, particularly among young adults (EAPC = 1.28%, P  < 0.001), whereas that attributable to smoking decreased most significantly (EAPC = -1.96%, P  < 0.001). High SDI countries contributed the most to this declined trend, however they possess the highest baseline ASRs. ASMR and ASDR continued to rise in middle and low-middle SDI countries. By 2050 young male adults show a significant upward trajectory in KC burden, while the declining trends were observed in the whole population. Conclusions This study highlights the urgent need to address the increasing KC burden among young adults, particularly males, as well as in high, middle, and low-middle SDI countries.

Background Patient-derived organoids provide a powerful platform for elucidating mechanisms of drug resistance and tumor evolution in hepatocellular carcinoma (HCC) and identifying novel therapeutic targets. Methods Transcriptomic sequencing was used to compare gene expression patterns between organoid-forming and non-forming HCC tissues, as well as between sorafenib-resistant organoids and sorafenib-sensitive counterparts. The TCGA-liver hepatocellular carcinoma (LIHC) cohort was used to screen for the key molecular drivers of HCC evolution from the overlapping differentially expressed genes. The effects of D-amino acid oxidase (DAO) on the growth, migration, invasion, apoptosis, and generation of H 2 O 2 were evaluated in HepG2 and SK-Hep-1 cell lines and human HCC organoids. The therapeutic efficacy of DAO against HCC growth and drug resistance was validated with xenograft mouse model and organoids, respectively. Results Expression level of DAO was significantly downregulated in HCC tissues that successfully formed organoids compared to those that failed, as well as in sorafenib-resistant organoids versus their parental counterparts. In the TCGA-LIHC cohort, DAO expression was significantly reduced in advanced-stage HCC tissues and was inversely correlated with stemness- and epithelial-mesenchymal transition (EMT)-related molecules. Lower DAO expression was associated with poor overall survival in patients with HCC. In HepG2 cells, DAO knockdown significantly enhanced cell proliferation. Ectopic DAO expression suppressed proliferation, migration, and invasion in HepG2 and SK-Hep-1 cells. D-alanine (D-Ala) supplementation further enhanced the anti-proliferative effect of overexpressed DAO, but did not significantly alter the DAO-mediated suppression of migration or invasion. Ectopic expression of DAO induced apoptosis via the generation of H 2 O 2 upon simultaneous supplementation of D-Ala into the culture medium; the addition of catalase, an H₂O₂-degrading enzyme, significantly reversed the D-Ala-induced effects. In BALB/c nude mouse models, HCC cells overexpressing DAO formed significantly smaller tumors than the control cells ( P  = 0.010), and this tumor-suppressive effect was further enhanced by D-alanine supplementation. Ectopic DAO expression restored sorafenib sensitivity in resistant organoids. Conclusion DAO appears to be a novel endogenous stemness repressor. The reduction in DAO is a critical molecular event in the evolution of HCC. Therapeutically, combined DAO and D-amino acid supplementation is a promising strategy for HCC treatment, particularly for reversing sorafenib resistance.

Cigarette smoke aggravates severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. However, the underlying mechanisms remain unclear. Here, they show that benzo[a]pyrene in cigarette smoke extract facilitates SARS‐CoV‐2 infection via upregulating angiotensin‐converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2). Benzo[a]pyrene trans ‐activates the promoters of ACE2 and TMPRSS2 by upregulating nuclear receptor subfamily 4 A number 2 (NR4A2) and promoting its binding of NR4A2 to their promoters, which is independent of functional genetic polymorphisms in ACE2 and TMPRSS2 . Benzo[a]pyrene increases the susceptibility of lung epithelial cells to SARS‐CoV‐2 pseudoviruses and facilitates the infection of authentic Omicron BA.5 in primary human alveolar type II cells, lung organoids, and lung and testis of hamsters. Increased expression of Nr4a2, Ace2, and Tmprss2, as well as decreased methylation of CpG islands at the Nr4a2 promoter are observed in aged mice compared to their younger counterparts. NR4A2 knockdown or interferon‐λ2/λ3 stimulation downregulates the expression of NR4A2, ACE2, and TMPRSS2, thereby inhibiting the infection. In conclusion, benzo[a]pyrene enhances SARS‐CoV‐2 infection by boosting NR4A2‐induced ACE2 and TMPRSS2 expression. This study elucidates the mechanisms underlying the detrimental effects of cigarette smoking on SARS‐CoV‐2 infection and provides prophylactic options for coronavirus disease 2019, particularly for the elderly population.

With the continuous scaling of CMOS technology, single-event multi-node upsets (MNU) induced by charge sharing has continued to occur in latches when hit by high-energy particles. This paper presents a quadruple-node upset (QNU) tolerant latch design (referred to as P-DICE latch) to achieve both high reliability and low area overhead. The P-DICE latch takes advantage of the error-blocking properties of Cross-Coupled Element and C Element to tolerate QNU, and achieves 100% self-recovery of SNU and DNU. Compared with previous eight MNU hardened latches, the P-DICE latch has the lowest overhead in terms of area, area-power-delay product (APDP), and area-power-delay soft error rate ratio product (APDSP), and has the highest critical charge. Moreover, the proposed P-DICE latch can tolerate QNU caused by high-energy particles to ensure the reliability of the circuit. Compared with eight MNU hardened latches, the proposed P-DICE latch achieves 24.58% reduction in area, 33.05% reduction in power, 17.19% reduction in delay, 48.29% reduction in area-power-delay product, 61.60% reduction in APDSP, and 142.82% improvement in critical charge on average.

Globally, primary liver cancer is the third leading cause of cancer death, and hepatocellular carcinoma (HCC) accounts for 75%-95%. The tumor microenvironment (TME), composed of the extracellular matrix, helper cells, immune cells, cytokines, chemokines, and growth factors, promotes the immune escape, invasion, and metastasis of HCC. Tumor metastasis and postoperative recurrence are the main threats to the long-term prognosis of HCC. TME-related therapies are increasingly recognized as effective treatments. Molecular-targeted therapy, immunotherapy, and their combined therapy are the main approaches. Immunotherapy, represented by immune checkpoint inhibitors (ICIs), and targeted therapy, highlighted by tyrosine kinase inhibitors (TKIs), have greatly improved the prognosis of HCC. This review focuses on the TME compositions and emerging therapeutic approaches to TME in HCC.Globally, primary liver cancer is the third leading cause of cancer death, and hepatocellular carcinoma (HCC) accounts for 75%-95%. The tumor microenvironment (TME), composed of the extracellular matrix, helper cells, immune cells, cytokines, chemokines, and growth factors, promotes the immune escape, invasion, and metastasis of HCC. Tumor metastasis and postoperative recurrence are the main threats to the long-term prognosis of HCC. TME-related therapies are increasingly recognized as effective treatments. Molecular-targeted therapy, immunotherapy, and their combined therapy are the main approaches. Immunotherapy, represented by immune checkpoint inhibitors (ICIs), and targeted therapy, highlighted by tyrosine kinase inhibitors (TKIs), have greatly improved the prognosis of HCC. This review focuses on the TME compositions and emerging therapeutic approaches to TME in HCC.

Background: Family members of Apolipoprotein B mRNA-editing enzyme catalytic 3 (APOBEC3) play critical roles in cancer evolution and development. However, the role of APOBEC3A in cervical cancer remains to be clarified. Methods: We used bioinformatics to investigate APOBEC3A expression and outcomes using The Cancer Genome Atlas (TCGA)-cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) dataset, GTEx, and GSE7803. Immunohistochemistry was then used to identify APOBEC3A's expression pattern. We performed Cell Counting Kit-8, wound-healing, Transwell, and flow cytometry assays to measure proliferation, migration, invasion, and apoptosis, respectively, using the SiHa and HeLa cell lines transfected with APOBEC3A. BALB/c nude mice were used to investigate the effects of APOBEC3A in vivo. The phosphorylated gamma-H2AX staining assay was applied to measure DNA damage. RNA sequencing (RNA-Seq) was applied to explore APOBEC3A-related signaling pathways. Results: APOBEC3A was more significantly expressed in cancer tissues than in adjacent normal tissues. Higher expression of APOBEC3A was associated with better outcomes in TCGA-CESC and GTEx. Immunohistochemistry showed that the expression of APOBEC3A was significantly higher in cancer tissues than in normal tissues. Transfection experiments showed that APOBEC3A inhibited proliferation, upregulated S-phase cells, inhibited migration and invasion, induced DNA damage, and promoted apoptosis. Overexpression of APOBEC3A inhibited tumor formation in the mouse model. RNA-seq analysis showed that ectopic expression of APOBEC3A inhibited several cancer-associated signaling pathways. Conclusions: APOBEC3A is significantly upregulated in cervical cancer, and higher expression of APOBEC3A is associated with better outcomes. APOBEC3A is a tumor suppressor whose overexpression induces apoptosis in cervical cancer.Background: Family members of Apolipoprotein B mRNA-editing enzyme catalytic 3 (APOBEC3) play critical roles in cancer evolution and development. However, the role of APOBEC3A in cervical cancer remains to be clarified. Methods: We used bioinformatics to investigate APOBEC3A expression and outcomes using The Cancer Genome Atlas (TCGA)-cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) dataset, GTEx, and GSE7803. Immunohistochemistry was then used to identify APOBEC3A's expression pattern. We performed Cell Counting Kit-8, wound-healing, Transwell, and flow cytometry assays to measure proliferation, migration, invasion, and apoptosis, respectively, using the SiHa and HeLa cell lines transfected with APOBEC3A. BALB/c nude mice were used to investigate the effects of APOBEC3A in vivo. The phosphorylated gamma-H2AX staining assay was applied to measure DNA damage. RNA sequencing (RNA-Seq) was applied to explore APOBEC3A-related signaling pathways. Results: APOBEC3A was more significantly expressed in cancer tissues than in adjacent normal tissues. Higher expression of APOBEC3A was associated with better outcomes in TCGA-CESC and GTEx. Immunohistochemistry showed that the expression of APOBEC3A was significantly higher in cancer tissues than in normal tissues. Transfection experiments showed that APOBEC3A inhibited proliferation, upregulated S-phase cells, inhibited migration and invasion, induced DNA damage, and promoted apoptosis. Overexpression of APOBEC3A inhibited tumor formation in the mouse model. RNA-seq analysis showed that ectopic expression of APOBEC3A inhibited several cancer-associated signaling pathways. Conclusions: APOBEC3A is significantly upregulated in cervical cancer, and higher expression of APOBEC3A is associated with better outcomes. APOBEC3A is a tumor suppressor whose overexpression induces apoptosis in cervical cancer.

We aimed to compare the association of metabolic dysfunction‐associated fatty liver disease (MAFLD), metabolic dysfunction‐associated steatotic liver disease (MASLD), alcohol‐related liver disease (ALD), metabolic dysfunction and ALD (MetALD), and MASLD with viral hepatitis (MASLD‐Viral) with risks of cirrhosis, liver cancer, and mortality. The data of 464,556 adults from the UK Biobank (UKB), 13,526 adults from the National Health and Nutrition Examination Survey (NHANES), and 2554 adults from BeijngFH Health Cohort Study (FHCS) were included. Adjusted hazard ratios (aHR) and odds ratios were calculated using Cox and Logistic regression models, respectively. Compared with non‐SLD, the risk of liver cancer increased from MetALD (aHR 1.70 [95% CI 1.37, 2.09]), MASLD (1.91 [1.66, 2.21]), MAFLD (2.01 [1.76, 2.29]), ALD (3.16 [2.54, 3.93]), to MASLD‐Viral (22.0 [10.8, 44.4]) in a stepwise manner in the UKB; the risk of all‐cause mortality increased from MetALD, MASLD, MAFLD, ALD, to MASLD‐Viral in the NHANES. The odds ratio of liver fibrosis increased from MASLD, MAFLD, to MASLD‐Viral in the FHCS. In patients with diabetes, metformin plus other drugs were associated with higher risks of cirrhosis, liver cancer, and all‐cause mortality in MASLD or MAFLD. Prevention rather than antiglycemic treatment is important for patients with diabetic MASLD or MAFLD. This study analyzed the UK Biobank, NHANES III, and FHCS data to assess the prognostic and associative effects of new steatotic liver disease nomenclatures. It found that MAFLD, MASLD, and MetALD were associated with higher risks of liver‐related conditions and mortality, with diabetes and certain antiglycemic medications further heightening these risks .